CASE REPORT

Disseminated Superficial Actinic Porokeratosis in a Patient with Psoriasis, after Long-Term Narrowband Ultraviolet B Phototherapy

Chang Yoon Sim, Ji Yeoun Shin, Sung Yul Lee, Young Lip Park

Department of Dermatology, Soonchunhyang University Bucheon Hospital, Bucheon, Korea

Porokeratosis is a rare epidermal disorder characterized by annular or linear hyperkeratotic plaques with slightly raised thread-like borders, and in most cases, atrophic centers. Disseminated superficial porokeratosis and disseminated superficial actinic porokeratosis (DSAP), which primarily involve sun-exposed areas, are common types of porokeratoses. Histologically, a column of parakeratotic cells, a so-called cornoid lamella, is a hallmark of porokeratosis. Porokeratosis is considered to result from the inability to eliminate an abnormal keratinocyte clone induced by genetic factors and various stimuli, including sunlight, artificial ultraviolet light, viral infections, immunosuppressive conditions (hematologic malignancies, organ transplants, or autoimmune disease), and immunosuppressive therapies. Here, we report a 59-year-old Korean woman with DSAP that developed after narrowband ultraviolet B (NB-UVB) therapy for psoriasis. Our case emphasizes the occurrence of DSAP due to NB-UVB that is able to induce local immunosuppression at the irradiated site; the pathogenesis of DSAP remains unclear. (Ann Dermatol 30(2) 211 ∼ 213, 2018)

Keywords
Porokeratosis, Psoriasis, Ultraviolet therapy

INTRODUCTION

Porokeratosis is a rare epidermal disorder characterized by annular or linear hyperkeratotic plaques, with slightly raised thread-like borders. The histologic characteristic of porokeratosis is the presence of “cornoid lamellae.” Porokeratosis is considered to occur as a result of the inability to eliminate an abnormal keratinocyte clone induced by genetic factors and various stimuli, including sunlight, artificial ultraviolet (UV) light, viral infections, and immunosuppressive conditions (hematologic malignancies, organ transplants, autoimmune disease, or immunosuppressant therapies). Disseminated superficial porokeratosis (DSP) and disseminated superficial actinic porokeratosis (DSAP), which primarily involve sun-exposed areas, are common types of porokeratoses that demonstrate multiple, small, asymptomatic lesions. Here, we report a case of DSAP arising after narrowband UVB (NB-UVB) psoriasis therapy. This may be the first reported case of DSAP arising after repeated exposure to NB-UVB in Korea.

CASE REPORT

A 59-year-old woman (skin type IV) had generalized plaque-type psoriasis for 40 years. She had primary hypertension and hyperlipidemia, but her general health was otherwise unremarkable. The patient’s family history did not include porokeratosis or psoriasis. Forty years prior to presentation, she had been treated with NB-UVB and systemic acitretin for 10 years. At that time, her symptoms improved and she discontinued treatment after she married and became pregnant. Twenty years later, her psoriasis recurred, and she was again treated with systemic acitretin and NB-UVB. Three years prior to presentation, she began only NB-UVB therapy, without oral medication,
but she experienced repeated improvement and aggravation cycles. At that time, her skin symptoms were suspected to indicate porokeratosis, and the treatment was stopped. She was then referred to our dermatology department. A dermatological examination revealed various annular, scaly patches and plaques, with raised keratotic margins (0.5 ~ 5.0 cm in diameter). The plaques were bilaterally located over her entire body (Fig. 1). Some lesions were small, annular plaques with sharp, elevated borders. Many larger plaques (approximately 5.0 cm long) were present on her right shin, and exhibited a typical psoriatic appearance of erythema and thick scales.

Histopathological examination of a biopsy specimen from a plaque with a thread-like border on her right leg showed the characteristic features of porokeratosis, including cornoid lamellae, irregularly arranged keratinocytes in the spinous layer, and superficial perivascular lymphocytic infiltration in the dermis (Fig. 2).

**DISCUSSION**

Porokeratosis is considered to be a chronic progressive disorder of keratinization with an unclear pathogenesis. The condition may be autosomally inherited, although most cases are idiopathic\(^1\). Two disseminated forms have been described: DSAP, which is the most common variant, and DSP, a non-actinic variant\(^5,6\). The condition typically manifests during the third and fourth decades of life. Clinically, multiple (> 50) small (<1 cm) annular plaques are observed, with thread-like borders; in most cases, atrophic centers are present, usually appearing in sun-exposed areas of skin\(^7\).

A column of parakeratotic cells, the so-called cornoid lamella, is a histological hallmark of porokeratosis, and a perivascular lymphohistiocytic infiltrate, which may be focally lichenoid, also presents\(^8\). Although the pathogenesis of porokeratosis is unknown, it may include a combination of genetic and environmental factors. Sun exposure, genetic susceptibility, and immunosuppression are the main factors triggering DSAP, presumably because of induced immunosuppression\(^9\). Development of DSAP after chronic UV exposure, including oral psoralens and UVA (PUVA), topical PUVA, broadband UVB, and NB-UVB psoriasis therapies and sun bathing, have also been reported\(^6,10-14\).

Dermatologically, NB-UVB is a useful treatment option for several skin diseases, including psoriasis, vitiligo, pityriasis rosea, and mycosis fungoides. NB-UVB therapy modulates cytokines, irradiates T cells (important for the prevention of porokeratotic clonal growth), and induces apoptosis; thus, the immune system is suppressed and inflammation is reduced\(^9,15-18\). Hence, focal immunosuppression may be induced by UV irradiation of the irradiated site. Following immunosuppression due to long-term NB-UVB phototherapy, genetically susceptible individuals have been documented to experience induced expression of abnormal epidermal cell clones, disruption of epidermal growth, and promotion of clonal cell proliferation\(^18\).

In conclusion, we reported a case of DSAP that developed in a patient with psoriasis, after long-term NB-UVB phototherapy. This may be the first reported case of DSAP occurring after repeated exposure to NB-UVB in Korea. Although this condition is uncommon, clinicians should be aware of the potential development of DSAP in patients receiving immunosuppressive treatments such as NB-UVB therapy.
ACKNOWLEDGMENT

This work was supported by the Soonchunhyang University Research Fund.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

REFERENCES

1. Kanitakis J, Euvrard S, Faure M, Claudy A. Porokeratosis and immunosuppression. Eur J Dermatol 1998;8:459-465.
2. Jung JY, Yeon JH, Ryu HS, Youn SW, Park KC, Huh CH. Disseminated superficial porokeratosis developed by immunosuppression due to rheumatoid arthritis treatment. J Dermatol 2009;36:466-467.
3. Neumann RA, Knobler RM, Metze D, Jurecka W. Disseminated superficial porokeratosis and immunosuppression. Br J Dermatol 1988;119:375-380.
4. Kawara S, Oiso N, Kawada A. Disseminated superficial actinic porokeratosis in a patient undergoing treatment with long-term narrowband ultraviolet B for psoriasis. J Dermatol 2011;38:585-587.
5. Chernosky ME, Anderson DE. Disseminated superficial actinic porokeratosis. Clinical studies and experimental production of lesions. Arch Dermatol 1969;99:401-407.
6. Takahashi H, Takahashi I, Linuma S, Honma M, Iizuka H. Disseminated superficial actinic porokeratosis in a psoriasis patient with a long-term sun-bathing habit. J Dermatol 2015;42:532-533.
7. Chernosky ME. Porokeratosis: report of twelve patients with multiple superficial lesions. South Med J 1966;59:289-294.
8. Milbetti V. Contributo allo studio della iipercheratosi dei canali sudoriferi (porokeratosis). G Ital Mal Vener 1893;28:313-355.
9. Murase J, Gilliam AC. Disseminated superficial actinic porokeratosis co-existing with linear and verrucous porokeratosis in an elderly woman: update on the genetics and clinical expression of porokeratosis. J Am Acad Dermatol 2010;63:886-891.
10. Reymond JL, Beani JC, Amblard P. Superficial actinic porokeratosis in a patient undergoing long-term PUVA therapy. Acta Derm Venereol 1980;60:539-540.
11. Lederman JS, Sober AJ, Lederman GS. Psoralens and ultraviolet A, immunosuppression, and porokeratosis. J Am Acad Dermatol 1986;14:284-285.
12. Hazen PG, Carney JF, Walker AE, Stewart JJ, Engstrom CW. Disseminated superficial actinic porokeratosis: appearance associated with photochemotherapy for psoriasis. J Am Acad Dermatol 1985;12:1077-1078.
13. Allen AL, Glaser DA. Disseminated superficial actinic porokeratosis associated with topical PUVA. J Am Acad Dermatol 2000;43:720-722.
14. Cockerell CJ. Induction of disseminated superficial actinic porokeratosis by phototherapy for psoriasis. J Am Acad Dermatol 1991;24:301-302.
15. Gilmour JW, Vestey JP, George S, Norval M. Effect of phototherapy and urocanic acid isomers on natural killer cell function. J Invest Dermatol 1993;101:169-174.
16. Sigmundsdottir H, Gudjonsson JE, Valdimarsson H. The effects of ultraviolet B treatment on the expression of adhesion molecules by circulating T lymphocytes in psoriasis. Br J Dermatol 2003;148:996-1000.
17. Tobin AM, Maguire B, Enright H, Kirby B. The effects of phototherapy on the numbers of circulating natural killer cells and T lymphocytes in psoriasis. Photodermatol Photoimmunol Photomed 2009;24:69-720.
18. Bencini PL, Tarantini A, Grimalt R, Ponticelli C, Caputo R. Porokeratosis and immunosuppression. Br J Dermatol 1995;132:74-78.